P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
Ruihao Huang(Army Medical University), X Zhang(Army Medical University), Han Xiao(Peking University), Xiaoqi Wang(Army Medical University), Jia Liu(Nanjing Medical University), Cheng Zhang(Hubei University of Medicine), Hongju Yan(Army Medical University), Lei Gao(Second Military Medical University), Maihong Wang(Army Medical University), Yingying Ma(Army Medical University), Gao Li(Army Medical University)
Cited by 5
Related Papers
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
|Nature Chemical Biology|2020|114
Metformin is a novel suppressor for transforming growth factor (TGF)-β1
|Scientific Reports|2016|96
Strategies to enhance CAR-T persistence
|Biomarker Research|2022|90